Interleukin-17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis

A Wang¹, N Hornick¹, Y Lim¹, J Gehlhausen¹, J Siegel¹, J Wang¹, F Foss², I Lim¹, A Zubek¹, L Milstone¹, A Galan^{1

3}, B King¹, W Damsky¹

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
² Department of Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.
³ Department of Pathology, Yale School of Medicine, New Haven, CT, USA.

A Wang et al. J Eur Acad Dermatol Venereol. 2020 Sep.

. 2020 Sep;34(9):e497-e499.

doi: 10.1111/jdv.16416. Epub 2020 May 6.

A Wang¹, N Hornick¹, Y Lim¹, J Gehlhausen¹, J Siegel¹, J Wang¹, F Foss², I Lim¹, A Zubek¹, L Milstone¹, A Galan^{1

3}, B King¹, W Damsky¹

¹ Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
² Department of Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.
³ Department of Pathology, Yale School of Medicine, New Haven, CT, USA.

No abstract available

References

1. McGeachyMJ, CuaDJ, GaffenSL. The IL-17 family of cytokines in health and disease. Immunity 2019; 50: 892-906.
1. OrrellKA, MurphreyM, KelmRC et al. Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program. J Am Acad Dermatol 2018; 79: 777-778.
1. NyckowskiT, CeilleyR, WilsonJ. Sarcoidosis developing during secukinumab therapy: case report. J Cutan Med 2017; 1: 5.
1. SambhariaM, MaggeT, RamakrishnaS. worsening of pulmonary sarcoidosis induced by ixekizumab: a rare paradox. Chest 2018; 154: 898A.
1. WangA, HornickN, LimY et al. IL-17 blockade downregulates NOD2 in skin and may promote ‘paradoxical’ sarcoidosis. J Eur Acad Dermatol Venereol 2020; https://doi.org/10.1111/jdv.16416